Adaptive radiotherapy compared with standard radiotherapy for bladder cancer
Tests adaptive radiotherapy, which adjusts each dose to bladder changes, in bladder cancer patients.
Plain-language title generated from the registry record
Registry title: Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)
Key facts
- Where
- Avignon, Dijon, Lille, Montpellier, Paris, Rennes, Rouen, Saint-Cloud, Saint-Herblain, Toulon, and Villeurbanne, FranceSee the 11 sites
Where in France
- Institut Sainte-CatherineAvignon, FranceTaking people
- Centre Georges François LeclercDijon, FranceNot yet recruiting
- Centre Oscar LambretLille, FranceTaking people
- Institut du Cancer de MontpellierMontpellier, FranceTaking people
- Hôpital TenonParis, FranceTaking people
- Centre Eugène MarquisRennes, FranceTaking people
- Centre Henri BecquerelRouen, FranceTaking people
- Institut CurieSaint-Cloud, FranceNot yet recruiting
- Institut de Cancérologie de l'OuestSaint-Herblain, FranceNot yet recruiting
- Centre de Radiothérapie Saint-LouisToulon, FranceTaking people
- Centre de Radiothérapie BayardVilleurbanne, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut du Cancer de Montpellier - Val d'Aurelle
- Trial code
- NCT07043543
- Record updated
- 9 November 2026
- Original description
Trimodal therapy (TMT) consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy is a therapeutic alternative in patients with Muscle-Infiltrating Bladder Cancer who are inoperable or refuse surgery. One of the main challenges of TMT is the planning and delivery of radiation therapy. Indeed, the bladder is a mobile hollow organ subject to repletion, with variations in size and shape during and between radiotherapy sessions. Standard radiotherapy techniques require large planning target volume margins around the bladder, which can be responsible for irradiation of a large volume of large and small bowel with grade 2 and 3 toxicities.Read full original descriptionShow less
Randomized Open Phase II Multienter Study Evaluating the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer
Trimodal therapy (TMT) consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy is a therapeutic alternative in patients with Muscle-Infiltrating Bladder Cancer who are inoperable or refuse surgery. One of the main challenges of TMT is the planning and delivery of radiation therapy. Indeed, the bladder is a mobile hollow organ subject to repletion, with variations in size and shape during and between radiotherapy sessions. Standard radiotherapy techniques require large planning target volume margins around the bladder, which can be responsible for irradiation of a large volume of large and small bowel with grade 2 and 3 toxicities.
Adaptive radiotherapy allows for the generation of a treatment fraction personalized to a patient's anatomical modification with margin reduction and improves the dosimetric quality of the delivered plans.
The hypothesis is that this improvement results in radiation-induced toxicity improvement.
Inclusion: Histologically proven muscle-infiltrating bladder cancer (de novo MIBC or after a history of non-muscle-invasive bladder cancer) or patients with initial high-grade T1 tumor showing Ta or T1 recurrence, or those with high-grade T1 after a course of intravesical biological therapy or chemotherapy; Age ≥ 18 years; Urothelial carcinoma (transitional cell carcinoma of the bladder, micropapillary, microcystic with trophoblastic differenciation) and squamous cell histological types are allowed; Stage T1-T4aN0M0; TransUrethral Resection of Bladder Tumor (TURBT) and Position Emission Tomography- scanner and X-ray Computed Tomography (PET-CT) or Computed Tomography scan of thorax/abdomen/pelvis (without carcinological anomaly) within 8 weeks prior to the start of radiation therapy (if TURBT was performed more than 6 weeks before the inclusion visit, a new TURBT or, at least, a cystoscopy showing no progression, no residual tumour or regrowth must be done); Suitable for radiotherapy; Eastern Cooperative Oncology Group/World Human Organisation (ECOG/WHO) performance status from 0 to 2; Negative pregnancy test (blood or urine), for women of childbearing age only; If the patient is sexually active, he/she must agree to use contraception deemed adequate and appropriate by the investigator throughout the period of study drug administration and 6 months after the end of treatment for both men and women; Affiliation to the French Social Security System; Dated, written and signed Informed consent.
Exclusion: Prior pelvic radiation therapy; Patients with previous or concomitant other malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years; Uncontrolled inflammatory bowel disease (ulcerative colitis or Crohn's disease); Uncontrolled immune or cardiac or pulmonary disease; Presence of endopenic stent; Inability to comply with the protocol; Grade 1 or greater baseline diarrhea; Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons; Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study; Pregnant or breast-feeding subjects.